Cargando…
Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital
BACKGROUND: In the last decade, there has been a revolution in chronic myeloid leukemia treatment with the introduction of tyrosine kinase inhibitors with imatinib mesylate becoming the frontline therapy. OBJECTIVE: To evaluate the therapeutic efficacy of imatinib mesylate in treating chronic myeloi...
Autores principales: | Cid, Danielle Maria Camelo, Magalhães, Silvia Maria Meira, Quixadá, Acy Telles de Souza, Honório, Rita Paiva Pereira, Costa, Paola Franssinetti Torres Ferreira, dos Reis, Samuel Roosevelt Campos, Carvalho, Selda Maria de Aguiar, Cid, David Antonio Camelo, Sucupira, Rafael Moura e, de Oliveira, Mariana Fátima Cabral |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Hematologia e
Hemoterapia
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905819/ https://www.ncbi.nlm.nih.gov/pubmed/24478603 http://dx.doi.org/10.5581/1516-8484.20130120 |
Ejemplares similares
-
Adherence to treatment with imatinib in chronic myeloid leukemia: a study of
the first decade of responses obtained at a Brazilian hospital
por: dos Reis, Samuel Roosevelt Campos, et al.
Publicado: (2013) -
Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010) -
Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015) -
The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005) -
Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)